These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A new approach to initial antiretroviral therapy: protease-sparing combination regimens. Hanna L BETA; 1998 Oct; ():9-13. PubMed ID: 11365999 [TBL] [Abstract][Full Text] [Related]
3. Cushing's syndrome mimicking lipodystrophy syndrome in a patient with AIDS. Bates SM; Page KB; Nakielny RA; Talbot MD Int J STD AIDS; 2002 Sep; 13(9):648-9. PubMed ID: 12243135 [No Abstract] [Full Text] [Related]
10. Perspectives on HAART: switch maintenance therapy. Leen CL Int J STD AIDS; 2003 Sep; 14(9):577-82. PubMed ID: 14511491 [TBL] [Abstract][Full Text] [Related]
11. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection]. van Leth F; Lange JM Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943 [TBL] [Abstract][Full Text] [Related]
12. Effects on growth after switching protease inhibitors to efavirenz in HIV-1-infected children. Rosso R; Di Biagio A; Dentone C; Bassetti M; Viscoli C; Parodi A; De Maria A Int J Antimicrob Agents; 2007 Feb; 29(2):228-30. PubMed ID: 17196369 [No Abstract] [Full Text] [Related]
13. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061 [TBL] [Abstract][Full Text] [Related]
15. Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution. Moyle G; Baldwin C AIDS Read; 2000 Aug; 10(8):479-85. PubMed ID: 10967808 [TBL] [Abstract][Full Text] [Related]
16. [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor]. MMW Fortschr Med; 2001 Apr; 143 Suppl 1():39. PubMed ID: 11373776 [No Abstract] [Full Text] [Related]
17. Comparison of NNRTIs in antiretroviral-experienced patients. Maggiolo F Int J STD AIDS; 2001 Nov; 12 Suppl 4():10-7. PubMed ID: 11589823 [No Abstract] [Full Text] [Related]
18. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load. Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884 [TBL] [Abstract][Full Text] [Related]
19. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Brinkman K; Smeitink JA; Romijn JA; Reiss P Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516 [TBL] [Abstract][Full Text] [Related]
20. Non-nucleoside reverse transcriptase inhibitors--an overview. Bell C; Matthews GV; Nelson MR Int J STD AIDS; 2003 Feb; 14(2):71-7. PubMed ID: 12662384 [No Abstract] [Full Text] [Related] [Next] [New Search]